Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 18/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 17/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.44 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402116 | 1.00 | ITGA4 (0.44) | ITGA4ITGB1ITGB7ITGA2ITGB3 | |
| SCHEMBL6156097 | 0.94 | ITGA4 (0.42) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6401299 | 0.89 | ITGA4 (0.49) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6401304 | 0.89 | ITGA4 (0.49) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6149667 | 0.88 | ITGB1 (0.48) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6152295 | 0.88 | ITGB1 (0.48) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6149675 | 0.88 | ITGB1 (0.48) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6152300 | 0.88 | ITGB1 (0.48) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6402881 | 0.88 | ITGB1 (0.49) | ITGA4ITGB1ITGB7ITGA2ITGB3 | |
| SCHEMBL6404278 | 0.88 | ITGB1 (0.49) | ITGA4ITGB1ITGB7ITGA2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | claimed |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
| EP-1495044-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. Uriach y Compania S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003084984-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. URIACH Y COMPANIA S.A. (ES) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | ITGA4 2/4885ITGB1 4/4885ITGB7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.